FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
Odyssey Therapeutics, Inc. ODTX — 8-K: Results of Operations and Financial Condition
neutral
The company reported $387 million in cash and cash equivalents, which is expected to fund operations into the second half of 2028, and announced progress in its pipeline, including additional analyses from the Phase 2a induction period for OD-001 and completion of IND-enabling studies for OD-002.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →